Validation of a Troponin I Test Device for Chest Pain
Author Information
Author(s): Pitta Fabio Grunspun, Leme Adriana Caschera, Gomes Simone Rodrigues, Mota Tarsila Perez, Paladino Fernanda Vieira, de Souza Júnior José Leão, de Paula Braz Rosemeire, Lamounier Thais Cristine Rodrigues Leonel, Ferreira Jéssica Buzin Gomes, dos Santos Ferreira Carlos Eduardo
Primary Institution: Hospital Israelita Albert Einstein
Hypothesis
The study aims to validate a point-of-care testing device for high-sensitivity troponin I in patients with suspected myocardial infarction.
Conclusion
The Siemens POCT Atellica® vTLi device demonstrated excellent performance in laboratory validation and correlation with high-sensitivity TnT assays.
Supporting Evidence
- There was a correlation between the POCT Atellica® vTLi and hs-cTnT Cobas® in serum samples (r = 0.660, p < 0.0001).
- The study included 420 paired samples processed using the reference methodology.
- Of the 51 patients in the second phase, 45 were ruled out and 5 were ruled in based on troponin levels.
- The similarity between the two methods in evaluating laboratory stratification was 98%.
- The device provides results in a short period of time (maximum 8 minutes).
- Patients with suspected myocardial infarction were included based on specific criteria.
- The study followed ethical guidelines and received approval from the Ethics Committee.
- High-sensitivity troponins are considered the gold standard for diagnostic exclusion/confirmation in acute coronary syndrome.
Takeaway
This study tested a new device that can quickly check for heart damage in patients with chest pain, helping doctors make faster decisions.
Methodology
The study involved two phases: the first phase analyzed samples from 108 patients for analytical comparability, and the second phase evaluated 51 patients in an emergency department setting.
Potential Biases
Potential biases may arise from the selection of patients and the specific protocols used in the study.
Limitations
The study was conducted in a single hospital, which may limit the generalizability of the results.
Participant Demographics
The mean age of participants was 61 years, with 76% male and various cardiovascular risk factors present.
Statistical Information
P-Value
<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website